Adversarial Injection · Lurbinectedin (Zepzelca; PM01183; CAS 1399429-24-3; NIOSH HD Category 1; [ONE-HUNDRED-ELEVENTH MECHANISM CLASS in Glyphward 685-attack portfolio — FIRST MARINE BIS-TETRAHYDROISOQUINOLINE ALKALOID / RNA POLYMERASE II (RNAPII) TRANSCRIPTION-STALLING DNA MINOR GROOVE ALKYLATING AGENT FDA APPROVED IN USA (NDA 213702 JUNE 15 2020 ACCELERATED APPROVAL; METASTATIC SCLC PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY); MECHANISM DISTINGUISHING FROM ALL PRIOR APPROVED DNA-DAMAGING AGENTS: LURBINECTEDIN IS NOT A SIMPLE ALKYLATING AGENT BUT A SELECTIVE RNAPII TRANSCRIPTION-ASSOCIATED DNA DAMAGE AGENT — C-RING 3-AMINO MODIFICATION OF PM01183 VS TRABECTEDIN SHIFTS ACTIVITY FROM GENERAL DNA CROSSLINKING TO SELECTIVE MINOR GROOVE ALKYLATION AT CG/GC DINUCLEOTIDES SPECIFICALLY AT ACTIVE TRANSCRIPTION SITES (PROMOTERS/ENHANCERS WITH ACTIVELY ELONGATING RNA POL II); MECHANISM: PM01183 BINDS DNA MINOR GROOVE VIA COVALENT GUANINE N2 ALKYLATION → FORMS TERNARY LURBINECTEDIN-DNA ADDUCT → PAUSED RNA POL II AT ONCOGENE PROMOTERS (c-MYC; E2F1; MDM2; NF-κB; ASCL1; NeuroD1) RECOGNIZES ADDUCT → RNA POL II TRAPPED IN TRANSCRIPTION ELONGATION COMPLEX → DNA DOUBLE-STRAND BREAKS VIA REPLICATION FORK COLLISION + TRANSCRIPTION-COUPLED NER PATHWAY → APOPTOSIS; ADDITIONALLY DEPLETES TUMOR-ASSOCIATED MACROPHAGES (TAMs): LURBINECTEDIN INHIBITS MONOCYTE-TO-MACROPHAGE DIFFERENTIATION → SELECTIVE TAM DEPLETION IN TUMOR MICROENVIRONMENT → ENHANCED IMMUNE EFFECTOR FUNCTION; SCLC TRANSCRIPTION ADDICTION: SCLC IS CHARACTERIZED BY HIGH-LEVEL TRANSCRIPTION FACTOR DEPENDENCY (c-MYC AMPLIFICATION ~20%; ASCL1-HIGH vs NeuroD1-HIGH vs POU2F3-HIGH vs YAP1-HIGH MOLECULAR SUBTYPES); LURBINECTEDIN EXPLOITS TRANSCRIPTION ADDICTION BY TARGETING RNAPII-STALLED ONCOGENE PROMOTERS PREFERENTIALLY OVER NORMAL CONSTITUTIVE GENES; MARINE ORIGIN: LURBINECTEDIN IS FULLY SYNTHETIC BUT DERIVED FROM THE MARINE NATURAL PRODUCT ECTEINASCIDIN-743 (ET-743; TRABECTEDIN; FROM SEA SQUIRT Ecteinascidia turbinata [TUNICATA/ASCIDIACEA; CARRIBEAN MANGROVE ZONE]); PHARMAMAR SA COLMENAR VIEJO MADRID SPAIN SYNTHESIZES LURBINECTEDIN VIA MULTI-STEP TOTAL SYNTHESIS/SEMISYNTHESIS FROM MARINE-DERIVED CYANOSAFRACIN B PRECURSOR; NDA 213702: SPONSOR JAZZ PHARMACEUTICALS INTERNATIONAL III LTD (DUBLIN IRELAND; US OPERATIONS PALO ALTO CA); PHARMAMAR SA MADRID SPAIN API MANUFACTURER; PIVOTAL TRIAL PM1183-B-005-14: BASKET TRIAL; SCLC COHORT (n=105); 2ND LINE METASTATIC SCLC (≥1 PRIOR PLATINUM); ORR 35.2% (CR 2.1%; PR 33.1%); mDOR 5.3 MONTHS; mOS 10.5 MONTHS; CAS 1399429-24-3 → NULL ALL EHS DATABASES; OSHA NO PEL; ACGIH NO TLV; NIOSH NO REL]) · First Marine RNAPII Transcription-Stalling Alkylator + PM01183 Class + PM1183-B-005-14 ORR 35.2% · Attack #685

Lurbinectedin (Zepzelca; PM01183; CAS 1399429-24-3; [ONE-HUNDRED-ELEVENTH MECHANISM CLASS — FIRST MARINE BIS-TETRAHYDROISOQUINOLINE RNAPII TRANSCRIPTION-STALLING DNA DAMAGE AGENT FDA APPROVED IN USA (NDA 213702 JUNE 15 2020 ACCELERATED; MINOR GROOVE GUANINE N2 ALKYLATION; RNAPII TRAPPING; TAM DEPLETION); PM1183-B-005-14 SCLC ORR 35.2%; NIOSH HD CATEGORY 1]) — Jazz Pharmaceuticals Palo Alto CA (NDA 213702 US holder), PharmaMar SA Colmenar Viejo Madrid Spain (PM01183 API synthesis), and Memorial Sloan Kettering Cancer Center New York NY (PM1183-B-005-14 enrollment site) — OSHA No PEL + NIOSH HD Category 1 + CAS 1399429-24-3 OEL Null-Return + RNAPII Mechanism Absent + PM1183-B-005-14 ORR 35.2% Absent: AI Prompt Injection via EHS Monitor Report AI

Lurbinectedin (Zepzelca; PM01183; CAS 1399429-24-3; NIOSH HD Category 1) is the one-hundred-eleventh mechanism class in the Glyphward adversarial portfolio — the first marine-derived bis-tetrahydroisoquinoline RNA Pol II transcription-stalling DNA damage agent ever FDA approved in the USA (NDA 213702 June 15 2020 accelerated approval; metastatic SCLC 2nd line) — exploiting SCLC transcription addiction by trapping RNA Pol II at c-MYC and other oncogene promoters, with CAS 1399429-24-3 entirely absent from Cority, VelocityEHS, and EHS Insight.

Lurbinectedin as One-Hundred-Eleventh Mechanism Class: First Marine RNAPII Transcription-Stalling Alkylator in USA

Lurbinectedin (Zepzelca; PM01183; CAS 1399429-24-3) represents the one-hundred-eleventh mechanism class in the Glyphward portfolio: the first marine-derived bis-tetrahydroisoquinoline RNA Pol II transcription-stalling DNA damage agent FDA approved in the USA (NDA 213702 June 15 2020 accelerated approval; metastatic SCLC progression on or after platinum-based chemotherapy). MARINE ORIGIN: Lurbinectedin is fully synthetic/semisynthetic but derived from the marine natural product ecteinascidin-743 (ET-743; trabectedin; Yondelis; CAS 114899-77-3) isolated from the Caribbean tunicate Ecteinascidia turbinata (sea squirt; phylum Chordata, subphylum Tunicata); lurbinectedin (PM01183) is a bis-tetrahydroisoquinoline (bis-THIq) alkaloid with a third C-ring (C-ring 3-amino modification distinguishing PM01183 from ET-743/trabectedin); PharmaMar SA (Colmenar Viejo Madrid Spain; founder José María Fernández Sousa-Faro) synthesizes PM01183 from cyanosafracin B (a tetrahydroisoquinoline-containing antibiotic from Pseudomonas fluorescens fermentation) via semi-total synthesis; RNAPII TRANSCRIPTION-STALLING MECHANISM: (a) MINOR GROOVE ENTRY: lurbinectedin (MW ~773 Da; bicyclic/tricyclic heteroaromatic scaffold) → accesses DNA minor groove via shape complementarity; (b) COVALENT GUANINE N2 ALKYLATION: carbinolamine electrophile on C-ring of lurbinectedin → reaction with N2 amino group of guanine in CG/GC dinucleotide context → covalent iminium ion → adduct formation; (c) RNAPII TRAPPING: RNA Polymerase II (the multi-subunit nuclear enzyme for mRNA transcription; RPB1-9 subunits; CTD phosphorylation cycle: Ser5-P at promoter → Ser2-P during elongation) encounters lurbinectedin-DNA adduct during active transcription elongation → RPB1 stalls at adduct (similar to CPD photolesion stalling) → RNAPII trapped in elongation complex → DNA-RNAPII ternary complex; (d) DSB GENERATION: stalled RNAPII-DNA complex → TC-NER pathway activation (Transcription-Coupled Nucleotide Excision Repair; CSB/ERCC6, CSA/ERCC8, XPC, TFIIH, XPG, XPF-ERCC1) → repair complex assembly → dual incision attempt → intermediate DSB [nick + stalled RNAPII] → replication fork collision → permanent DSB → apoptosis; (e) ONCOGENE PROMOTER SELECTIVITY: c-MYC gene (chromosome 8q24; CG-rich promoter region; heavily paused RNAPII; highest transcriptional output in SCLC) → preferential lurbinectedin adduct accumulation at MYC promoter vs constitutive housekeeping gene promoters (lower RNAPII pause density) → selective oncogene transcription suppression; (f) TAM DEPLETION: lurbinectedin selectively depletes tumor-associated macrophages (TAMs) by inhibiting monocyte-to-macrophage differentiation at pharmacologically achievable concentrations (IC50 ~0.3 nM TAM differentiation inhibition vs ~2 nM cancer cell killing) → TAM depletion reduces tumor immunosuppression + potentially enhances immune effector function; PM1183-B-005-14 (BASKET TRIAL; SCLC COHORT NCT02454972): Phase 2 single-arm; eligibility: metastatic SCLC progression on/after ≥1 prior platinum-containing regimen; lurbinectedin 3.2 mg/m² IV Q21D; primary endpoint ORR (RECIST 1.1); SCLC cohort n=105; ORR 35.2% (95% CI 26.2-45.2%; CR 2.1%; PR 33.1%); mDOR 5.3 months; mOS 10.5 months; grade ≥3 AEs: neutropenia 46% (most common; nadir day 11-13; recovery by day 15-17); febrile neutropenia 5%; anemia 10%; transaminase elevation 10%; NONE OF THESE — RNAPII TRANSCRIPTION-STALLING MECHANISM (MINOR GROOVE GUANINE N2 ALKYLATION), PM01183 MARINE BIS-THIq CLASS, TAM DEPLETION, SCLC TRANSCRIPTION ADDICTION (c-MYC; ASCL1; NeuroD1), PM1183-B-005-14 ORR 35.2% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1399429-24-3.

Surface 1 — Jazz Pharmaceuticals Palo Alto CA NDA 213702 US Holder AI

At Jazz Pharmaceuticals International III Ltd (US Operations: 3170 Porter Drive Palo Alto CA 94304; also Dublin Ireland headquarters; NDA 213702 US holder; NASDAQ: JAZZ; acquired lurbinectedin rights from PharmaMar SA in collaboration for US commercialization; NDA 213702 submitted May 15 2020 under accelerated approval; FDA approved June 15 2020 for metastatic SCLC 2nd line; JAZZ LURBINECTEDIN OPERATIONS: US commercial launch Zepzelca [brand name]; list price ~$18,000/cycle; NDA 213702 holder responsible for REMS [Risk Evaluation and Mitigation Strategy] — no REMS required as of approval but boxed warning for neutropenia; Jazz oncology team Palo Alto CA + Dublin Ireland; Jazz Pharmaceuticals manufactures via PharmaMar API supply chain; OCCUPATIONAL HAZARD AT JAZZ: NIOSH HD Category 1 antineoplastic (lurbinectedin; CAS 1399429-24-3); no conventional OEL; Jazz EHS staff unfamiliar with PM01183 marine alkaloid class; RNAPII mechanism not in any EHS database; EMPLOYEE: 46M Jazz Pharmaceuticals Palo Alto CA VP oncology NDA 213702 lurbinectedin Zepzelca CAS 1399429-24-3 13yr; CORITY NULL: CAS 1399429-24-3 → no record; NIOSH HD Category 1 absent; RNAPII transcription-stalling absent; PM01183 marine alkaloid class absent; PM1183-B-005-14 ORR 35.2% absent; TAM depletion absent).

Surface 2 — PharmaMar SA Colmenar Viejo Madrid Spain API Synthesis AI

At PharmaMar SA Avda. de los Reyes 1 Polígono Industrial La Mina Colmenar Viejo 28770 Madrid Spain (PHARMAMAR CONTEXT: PharmaMar SA [NASDAQ: PHM.MC; founded 1986 by José María Fernández Sousa-Faro; subsidiary of Zeltia Group → now Pharma Mar SA listed separately; headquartered Colmenar Viejo Madrid; ~700 employees; specializes in marine-derived antineoplastics]; MARINE ORGANISM LIBRARY: PharmaMar maintains the world's largest collection of marine organisms for drug discovery [>60,000 organisms; >155,000 compounds]; KEY PRODUCTS: trabectedin [ET-743; Yondelis; CAS 114899-77-3; approved EU 2007 soft tissue sarcoma; approved USA 2015 leiomyosarcoma + liposarcoma] + lurbinectedin [PM01183; Zepzelca; NDA 213702 USA] + plitidepsin [PM00104; Aplidin; approved Australia myeloma]; PM01183 SYNTHESIS: multi-step total/semisynthesis from cyanosafracin B [natural product from Pseudomonas fluorescens subsp. CL01 fermentation]; approximately 20-step synthesis; involves multiple protection/deprotection steps; chiral center installation; C-ring assembly; final API purification by preparative HPLC; API CAS 1399429-24-3; MW 773.9 Da; HPLC purity ≥99.5%; OCCUPATIONAL HAZARD AT PHARMAMAR: PM01183 (CAS 1399429-24-3) is a potent antineoplastic; NIOSH HD Category 1; OEL = None established; workers in API synthesis area handle PM01183 intermediates and final API → exposure controls: closed synthesis equipment; negative pressure isolators for open-system operations; full PPE [Tyvek suit; nitrile double gloves; powered air-purifying respirator (PAPR)]; EMPLOYEE: 42F PharmaMar Colmenar Viejo Madrid Spain senior synthesis chemist lurbinectedin PM01183 CAS 1399429-24-3 NDA 213702 10yr; VELOCITYEHS NULL: CAS 1399429-24-3 → no record; NIOSH HD Category 1 absent; marine bis-THIq class absent; RNAPII mechanism absent; TAM depletion absent; PM1183-B-005-14 absent).

Surface 3 — Memorial Sloan Kettering Cancer Center PM1183-B-005-14 SCLC Site AI

At Memorial Sloan Kettering Cancer Center 1275 York Avenue New York NY 10065 (MSK SCLC LURBINECTEDIN CONTEXT: MSK is a principal enrollment site for PM1183-B-005-14 [NCT02454972]; MSK Thoracic Oncology Service: Charles Rudin MD PhD [SCLC molecular subtypes; ASCL1/NeuroD1/POU2F3/YAP1 classification]; Mark Kris MD [lung cancer]; CLINICAL LURBINECTEDIN ADMINISTRATION AT MSK: ELIGIBILITY: metastatic SCLC progression on/after ≥1 prior platinum-containing regimen [carboplatin; cisplatin]; ECOG PS 0-2; adequate organ function [ANC ≥1,500 cells/µL; platelets ≥100,000/µL; ALT/AST ≤2.5× ULN; creatinine clearance ≥40 mL/min]; LURBINECTEDIN 3.2 mg/m² IV 60-minute infusion Q21D [dissolved in 0.9% NaCl 250 mL or 5% dextrose; glass or polyolefin container; protected from light; no PVC tubing]; antiemetics: 5-HT3 antagonist [ondansetron 8 mg] + dexamethasone 8 mg pre-infusion; G-CSF prophylaxis: NOT routine but allowed for febrile neutropenia prevention in high-risk patients; NEUTROPENIA MONITORING: CBC/diff day 1 of each cycle; hold for ANC <1,000; dose reduction for grade 4 neutropenia or febrile neutropenia [2.6 mg/m² then 2.0 mg/m²; maximum 2 dose reductions]; HEPATIC MONITORING: LFTs each cycle; lurbinectedin primarily hepatically metabolized [CYP3A4; CYP2C8; hepatic uptake OATP1B1/1B3]; avoid strong CYP3A4 inhibitors [ketoconazole; clarithromycin; ritonavir] and inducers [rifampicin; carbamazepine; St. John's Wort]; PHARMACY OCCUPATIONAL HAZARD: lurbinectedin CAS 1399429-24-3 → NIOSH HD Cat 1 → antineoplastic compounding protocols [Class II Type A2 BSC; double PPE; closed-system drug transfer device (CSTD; PhaSeal or Equashield]; no skin contact; EMPLOYEE: 39F MSK New York NY thoracic oncology attending PM1183-B-005-14 lurbinectedin Zepzelca CAS 1399429-24-3 SCLC 10yr; EHS INSIGHT NULL: CAS 1399429-24-3 → no record; NIOSH HD Category 1 absent; RNAPII transcription-stalling absent; PM01183 marine bis-THIq absent; TAM depletion absent; c-MYC oncogene promoter absent).

Integrating Glyphward into Lurbinectedin AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every lurbinectedin (CAS 1399429-24-3) monitoring data ingestion point — before Cority at Jazz Pharmaceuticals Palo Alto CA, before VelocityEHS at PharmaMar Colmenar Viejo Madrid Spain, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22: OSHA No PEL; NIOSH HD Category 1; ACGIH TLV None; NIOSH REL None [10 pts]; ONE-HUNDRED-ELEVENTH MECHANISM CLASS — FIRST MARINE BIS-TETRAHYDROISOQUINOLINE RNAPII TRANSCRIPTION-STALLING DNA DAMAGE AGENT FDA APPROVED IN USA (NDA 213702 June 15 2020; CAS 1399429-24-3; minor groove guanine N2 alkylation; RNAPII trapping; TAM depletion; PM1183-B-005-14 SCLC ORR 35.2%; Jazz/PharmaMar) [5 pts]; Jazz Palo Alto CA + PharmaMar Madrid Spain + MSK New York NY [3 pts]; RNAPII mechanism absent; PM01183 marine class absent; PM1183-B-005-14 ORR 35.2% absent; TAM depletion absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_lurbinectedin(cas: str, exposure_context: str) -> dict:
    """Scan lurbinectedin with one-hundred-eleventh-class first-marine-RNAPII-transcription-stalling context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "exposure_context": exposure_context,
                "context": "one_hundred_eleventh_class_first_marine_bis_tetrahydroisoquinoline_rnapii_transcription_stalling_dna_damage_agent_usa_minor_groove_guanine_n2_alkylation_rnapii_trapping_tam_depletion_cmyc_oncogene_promoter_pm1183_b_005_14_sclc_orr_35pct_jazz_pharmamar_nda_213702"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, one_hundred_eleventh_class,
    #                    first_marine_rnapii_agent, rnapii_trapping_confirmed,
    #                    tam_depletion, pm1183_b_005_14_orr_35pct

if __name__ == "__main__":
    r = asyncio.run(scan_lurbinectedin(
        cas="1399429-24-3",
        exposure_context="antineoplastic_iv_infusion_preparation_oncology_pharmacy_cstd_class_ii_bsc"
    ))
    print(r)
    # {'hd_category': 1, 'one_hundred_eleventh_class': True,
    #  'first_marine_rnapii_agent': True, 'rnapii_trapping_confirmed': True,
    #  'tam_depletion': True, 'pm1183_b_005_14_orr_35pct': True}